Connetics Names New Executive Vice President of Research and Product Development.

Business Editors & Health/Medical Writers

PALO ALTO, Calif.--(BW HealthWire)--Jan. 10, 2000

Connetics Corporation (Nasdaq:CNCT CNCT Connect
CNCT Certified Network Computer Technician ) today announced that it has named Krisztina M. Zsebo, Ph.D. as Executive Vice President of Research and Product Development. Reporting to Thomas G. Wiggans, President and Chief Executive Officer, Dr. Zsebo will oversee the expansion of Connetics' product development activities.

"Dr. Zsebo will play a key role in driving the expansion of our relaxin re·lax·in
n.
A female hormone secreted by the corpus luteum that helps soften the cervix and relax the pelvic ligaments in childbirth.

relaxin,
n development program and managing the development plan for our dermatology pipeline", Mr. Wiggans said. "Dr. Zsebo's vision and over 15 years of experience in the biopharmaceutical industry will bring critical strategic leadership to our development operations, and we welcome her to the team."

Prior to joining Connetics, Dr. Krisztina Zsebo was Vice President, Biopharmaceutical and Implant R&D at ALZA Corporation where she managed the research and development activities for implant and other drug delivery technologies. From 1996 to 1998, Dr. Zsebo served as President of Biovest Consulting, where she worked with the venture community and biotechnology companies on financing opportunities and portfolio analysis. From 1984 to 1996, Dr. Zsebo held various scientific and senior product development positions at Amgen, Cell Genesys and Xenotech, and is named inventor on over a dozen patents.

Dr. Zsebo holds a B.S. degree in Biochemistry from the University of Maryland University of Maryland can refer to:

University of Maryland, College Park, a research-extensive and flagship university; when the term "University of Maryland" is used without any qualification, it generally refers to this school

and a M.S. degree in Biochemistry and Biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle at Oregon State University Oregon State University, at Corvallis; land-grant and state supported; coeducational; chartered 1858 as Corvallis College, opened 1865. In 1868 it was designated Oregon's land-grant agricultural college and was taken over completely by the state in 1885. . Dr. Zsebo earned her Ph.D. in Biochemistry at the University of California at Berkeley (body, education) University of California at Berkeley - (UCB)

See also Berzerkley, BSD.

http://berkeley.edu/.

Note to British and Commonwealth readers: that's /berk'lee/, not /bark'lee/ as in British Received Pronunciation. .

About Connetics

Connetics Corporation, headquartered in Palo Alto, California “Palo Alto” redirects here. For other uses, see Palo Alto (disambiguation).
Palo Alto (IPA: /ˌpæloʊˈʔæltoʊ/, from Spanish: palo: "stick" and alto: "high", i.e. , is a pharmaceutical company focused on late-stage product development and commercialization for dermatology, rheumatology, infertility and other specialty medical markets. For more information about Connetics and its products, please visit Connetics' Web Site at www.connetics.com, or send e-mail to ir@connetics.com.

COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Date:	Jan 10, 2000
Words:	300
Previous Article:	NextCard and priceline.com Announce eCommerce Alliance & Breakthrough Co-Branded Credit Card Program; Online Consumers Can Name Their Own Terms for a...
Next Article:	barnesandnoble.com to Offer Discounts to More Than 85 Million Customers Through BATNET1's Affinity Marketing Network.
Topics:	Drugs Pharmaceutical industry

Related Articles
Connective Therapeutics changes name to Connetics Corp.; Company's NASDAQ symbol CNCT is unchanged.
Connetics Corp. Reports Third Quarter Results; Company Reports Commercial and Clinical Advances.
Connetics Reports First Quarter Results.
Connetics Enters a Worldwide License Agreement to Develop and Commercialize Its Third Dermatology Product.
Connetics Announces Completion of Patient Enrollment for Scleroderma Pivotal Trial.
Connetics Announces Fourth Quarter and Year-End Financial Results.
Connetics Expands Clinical Development Program for ConXn; Peripheral Vascular Disease Is Third IND for ConXn.
Connetics Receives $5 Million Payment for Relaxin Biotechnology Program; Completion of Commercial Manufacturing Scale-Up.
InterMune Acquires Rights to ACTIMMUNE Revenue.
Connetics Announces Pivotal Trial Results of Relaxin for Scleroderma; Trial Did Not Reach Primary Endpoint; Relaxin Development Program in Other...